A secondary analysis of the CASSINI trial finds that rivaroxaban is an effective thromboprophylactic for patients with pancreatic cancer receiving systemic therapy.
Can exercise intervention reduce racial and socioeconomic disparities in outcomes of breast cancer survivors over age 65? IMPROVE study is ongoing.
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Low CD30 expression in non-Hodgkin’s lymphoma patients does not predict low response to brentuximab vedotin, shows new study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
Financial navigators are reducing the financial burden of patients treated at Cleveland Clinic Cancer Center. In the past three years, copay assistance has increased 70% and funds collected to pay patients’ out-of-pocket costs have doubled.
In high-risk resected oral cavity squamous cell carcinoma, median disease-free survival doubles when patients receive 200 mg/m2 or more of cisplatin along with radiation therapy, shows one study.
See these presentations by Cleveland Clinic Cancer Center staff at ASCO 2019.
A phase 2 trial demonstrates promising results in patients with glioblastoma who take SurVaxM, an immunotherapy vaccine that targets survivin.